04:46 AM EDT, 09/09/2024 (MT Newswires) -- Savara (SVRA) said Sunday new data from a phase 3 study showed that its molgramostim experimental therapy showed significant improvement in disease severity scores compared with placebo in patients with autoimmune pulmonary alveolar proteinosis, a lung disease that causes shortness of breath.

The trial previously met its primary endpoint, showing statistically significant improvement in percent predicted diffusing capacity of the lungs for carbon monoxide versus placebo at week 24 and week 48.

Savara said it plans to complete the submission of a biologics license application for molgramostim in autoimmune pulmonary alveolar proteinosis in H1 2025.

Shares of the company were up 8.8% in premarket activity Monday.

Price: 4.4900, Change: +0.39, Percent Change: +8.82